EA200800015A1 - Аминопиримидины в качестве модуляторов киназы - Google Patents

Аминопиримидины в качестве модуляторов киназы

Info

Publication number
EA200800015A1
EA200800015A1 EA200800015A EA200800015A EA200800015A1 EA 200800015 A1 EA200800015 A1 EA 200800015A1 EA 200800015 A EA200800015 A EA 200800015A EA 200800015 A EA200800015 A EA 200800015A EA 200800015 A1 EA200800015 A1 EA 200800015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
trkb
flt3
kit
present
Prior art date
Application number
EA200800015A
Other languages
English (en)
Inventor
Майкл Дэвид Гаул
Гочжан Сюй
Кристиан Эндрю Бауманн
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200800015A1 publication Critical patent/EA200800015A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Настоящее изобретение относится к производным аминопиримидина формулы I, где R, В, Z, Q, p, q и Rимеют значения, как описано в настоящем описании, к применению таких соединений в качестве модуляторов протеинтирозинкиназы, особенно в качестве ингибиторов FLT3 и/или c-kit, и/или TrkB, к применению таких соединений для снижения или ингибирования киназной активности FLT3 и/или c-kit, и/или TrkB в клетке или у субъекта и к применению таких соединений для предупреждения или лечения у субъекта пролиферативного клеточного нарушения и/или нарушений, связанных с FLT3 и/или c-kit, и/или TrkB. Настоящее изобретение, кроме того, относится к фармацевтическим композициям, содержащим соединения согласно настоящему изобретению, и к способам лечения состояний, таких как раковые заболевания и другие пролиферативные клеточные нарушения.
EA200800015A 2005-06-10 2006-06-07 Аминопиримидины в качестве модуляторов киназы EA200800015A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16
PCT/US2006/022165 WO2006135644A1 (en) 2005-06-10 2006-06-07 Aminopyrimidines as kinase modulators

Publications (1)

Publication Number Publication Date
EA200800015A1 true EA200800015A1 (ru) 2008-06-30

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800015A EA200800015A1 (ru) 2005-06-10 2006-06-07 Аминопиримидины в качестве модуляторов киназы

Country Status (17)

Country Link
US (1) US20060281764A1 (ru)
EP (1) EP1896029A1 (ru)
JP (1) JP2008543760A (ru)
KR (1) KR20080028911A (ru)
AR (1) AR053895A1 (ru)
AU (1) AU2006258054A1 (ru)
BR (1) BRPI0611963A2 (ru)
CA (1) CA2611470A1 (ru)
EA (1) EA200800015A1 (ru)
EC (1) ECSP077991A (ru)
GT (1) GT200600248A (ru)
IL (1) IL187693A0 (ru)
NI (1) NI200700316A (ru)
NO (1) NO20080163L (ru)
PE (1) PE20070076A1 (ru)
TW (1) TW200718693A (ru)
WO (1) WO2006135644A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615880A2 (pt) * 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
ATE543498T1 (de) 2006-09-08 2012-02-15 Hoffmann La Roche Benzotriazol kinasemodulatoren
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
CN101674833A (zh) * 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
US20110275094A1 (en) * 2008-11-06 2011-11-10 Gunawardane Ruwanthi N Phosphorylated fms-related tyrosine kinase 3 biomarker assay
EP2352730A4 (en) * 2008-11-07 2012-04-25 Lundbeck & Co As H BIOLOGICALLY ACTIVE AMIDES
EP3461824B1 (en) 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
ES2850349T3 (es) * 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
KR20190121404A (ko) * 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
EP3752498B1 (en) * 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
TW202115008A (zh) 2019-08-14 2021-04-16 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
CN117043149A (zh) 2021-02-17 2023-11-10 克林提克斯医药股份有限公司 促生长素抑制素调节剂的结晶形式

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498165B1 (en) * 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Also Published As

Publication number Publication date
EP1896029A1 (en) 2008-03-12
PE20070076A1 (es) 2007-02-09
TW200718693A (en) 2007-05-16
JP2008543760A (ja) 2008-12-04
NI200700316A (es) 2009-03-03
AR053895A1 (es) 2007-05-23
CA2611470A1 (en) 2006-12-21
AU2006258054A1 (en) 2006-12-21
WO2006135644A1 (en) 2006-12-21
NO20080163L (no) 2008-03-07
ECSP077991A (es) 2008-01-23
BRPI0611963A2 (pt) 2010-10-13
GT200600248A (es) 2007-03-14
KR20080028911A (ko) 2008-04-02
US20060281764A1 (en) 2006-12-14
IL187693A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
EA200800015A1 (ru) Аминопиримидины в качестве модуляторов киназы
EA200800018A1 (ru) Аминопиримидины в качестве модуляторов киназы
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
EA200800017A1 (ru) Алкилхинолиновые и алкилхиназолиновые модуляторы киназы
TNSN08278A1 (en) Triazolopyridazines as tyrosine kinase modulators
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
TW200621721A (en) Methods of preparing indazole compounds
EA200601894A1 (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
DE602006020293D1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin-kinasen nützlich sind
ATE465165T1 (de) Pyrimidothienindazole als tyrosinkinasehemmer des epidermalen wachstumsfaktors
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa